Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

More documents

Recommendations

Info

Saffran, D. C. and Afar, D. E. Proc Natl Acad Sci USA 1999; 96: 14523±8. 37 Su, Z. Z., Lin, J., Shen, R., Fisher, P. E., Goldstein, N. I. and Fisher, P. B. Proc Natl Acad Sci USA 1996; 93: 7252± 7. 38 Lyne, J. C., Melhem, M. F., Finley, G. G., Wen, D., Liu, N., Deng, D. H. and Salup, R., Cancer J Sci Am 1997; 3: 21±30. 39 Signoretti, S., Montironi, R., Manola, J., Altimari, A.,Tam, C., Bubley, G., Balk, S.,Thomas, G., Kaplan, I., Hlatky, L., Hahnfeldt, P., Kantoff, P. and Loda, M. J Natl Cancer Inst 2000; 92: 1918±25. 40 Mitsuyasu, R. T., Anton, P. A., Deeks, S. G., Scadden, D. T., Connick, E., Downs, M. T., Bakker, A., Roberts, M. R., June, C. H., Jalali, S., Lin, A. A., Pennathur-Das, R. and Hege, K. M. Blood 2000; 96: 785±93. 41 Warren, R., Fisher, G. and Bergaland, E. Abstracts of the 7th Int Conf on Gene Therapy of Cancer 1998. Cancer Gene Therapy 1998; 5: Suppl. 6, 1±35. 42 Junghans, R., Safa, M. and Huberman, M. Proc Am Ass Cancer Res 2000; 41: 543. 43 Kershaw, M. H.,Westwood, J. A., Zhu, Z.,Witte, L., Libutti, S. K. and Hwu, P. Hum Gene Ther 2000; 11: 2445±52. 44 Darcy, P. K., Kershaw, M. H., Trapani, J. A. and Smyth, M. J. Eur J Immunol 1998; 28: 1663±72. 45 Hombach, A., Koch, D., Sircar, R., Heuser, C., Diehl,V., Kruis,W., Pohl, C. and Abken, H. Gene Ther 1999; 6: 300±4. 46 Nolan, K.,Yun, C., Akamatsu,Y., Murphy, J., Leung, S., Beecham, E. and Junghans, R. Clin Cancer Res 1999; 5: 3928±3941. 47 Hombach, A., Schneider, C., Sent, D., Koch, D.,Willemsen, R. A., Diehl,V., Kruis,W., Bolhuis, R. L., Pohl, C. and Abken, H. Int J Cancer 2000; 88: 115± 20. 48 Beecham, E. J., Ma, Q., Ripley, R. and Junghans, R. P. J Immunother 2000; 23: 631±42. 49 Kuroki, M., Arakawa, F., Khare, P. D., Liao, S., Matsumoto, H., Abe, H. and References Imakiire, T. Anticancer Res 2000; 20: 4067±71. 50 Haynes, N. M., Snook, M. B., Trapani, J. A., Cerruti, L., Jane, S. M., Smyth, M. J. and Darcy, P. K. J Immunol 2001; 166: 182±7. 51 Jensen, M., Tan, G., Forman, S., Wu, A. M. and Raubitschek, A. Biol Blood Marrow Transplant 1998; 4: 75± 83. 52 Hombach, A., Heuser, C., Sircar, R., Tillmann, T., Diehl,V., Pohl, C. and Abken, H. Cancer Res 1998; 58: 1116±9. 53 Hombach, A., Heuser, C., Sircar, R., Tillmann, T., Diehl,V., Pohl, C. and Abken, H. J Immunother 1999; 22: 473±80. 54 Hekele, A., Dall, P., Moritz, D., Wels,W., Groner, B., Herrlich, P. and Ponta, H. Int J Cancer 1996; 68: 232±8. 55 Dall, P., Hekele, A., Beckmann, M. W., Bender, H. G., Herrlich, P. and Ponta, H. Gynecol Oncol 1997; 66: 209± 16. 56 Daly, T., Royal, R. E., Kershaw, M. H., Treisman, J.,Wang, G., Li,W., Herlyn, D., Eshhar, Z. and Hwu, P. Cancer Gene Ther 2000; 7: 284±91. 57 Ren-Heidenreich, L., Hayman, G. T. and Trevor, K. T. Hum Gene Ther 2000; 11: 9±19. 58 Hwu, P., Shafer, G., Treisman, J., Schindler, D., Gross, G., Cowherd, R., Rosenberg, S. and Eshhar, Z. J Exp Med 1993; 178: 361±366. 59 Parker, L. L., Do, M. T.,Westwood, J. A., Wunderlich, J. R., Dudley, M. E., Rosenberg, S. A. and Hwu, P. Hum Gene Ther 2000; 11: 2377±87. 60 Weijtens, M. E.,Willemsen, R. A., Valerio, D., Stam, K. and Bolhuis, R. L. J Immunol 1996; 157: 836±43. 61 Weijtens, M. E., Hart, E. H. and Bolhuis, R. L. Gene Ther 2000; 7: 35±42. 62 Weijtens, M. E.,Willemsen, R. A., Hart, E. H. and Bolhuis, R. L. Gene Ther 1998; 5: 1195±203. 63 Yun, C. O., Nolan, K. F., Beecham, E. J., Reisfeld, R. A. and Junghans, R. P., Neoplasia 2000; 2: 449±59. 64 Reinhold, U., Liu, L., Ludtke-Handjery, H. C., Heuser, C., Hombach, A., Wang, X., Tilgen,W., Ferrone, S. and 297
298 14 The T-Body Approach: Towards Cancer Immuno-Gene Therapy Abken, H. J Invest Dermatol 1999; 112: 744±50. 65 Mezzanzanica, D., Canevari, S., Mazzoni, A., Figini, M., Colnaghi, M. I., Waks,T., Schindler, D. G. and Eshhar, Z. Cancer Gene Ther 1998; 5: 401±7. 66 Hombach, A., Heuser, C., Sircar, R., Tillmann, T., Diehl,V., Kruis,W., Pohl, C. and Abken, H. Gastroenterology 1997; 113: 1163±70. 67 Patel, S. D., Ge,Y., Moskalenko, M. and McArthur, J. G. J Immunother 2000; 23: 661±8.
Page 1 and 2:
Cancer Immune Therapie: Current and
Page 3 and 4:
Editors: Dr. Gernot Stuhler Univers
Page 5 and 6:
VI Preface Recent years have seen a
Page 7 and 8:
VIII Contents 2.5.3 Antigens Encode
Page 9 and 10:
X Contents 6.4.2 Natural Killer (NK
Page 11 and 12:
XII Contents 9.6 Loading DC with An
Page 13 and 14:
XIV Contents 14.2.2.1 Cancer-specif
Page 15 and 16:
List of Contributors Richard Bucala
Page 17 and 18:
Color Plates Fig. 5.2 The MHC class
Page 19 and 20:
Fig. 5.5 Different immune effector
Page 21 and 22:
Fig. 5.17 Possible pathway for the
Page 23 and 24:
Fig. 6.2 T lymphocytes in the tumor
Page 25 and 26:
Index a acidic and basic fibroblast
Page 27 and 28:
±, see also tumors cationic lipids
Page 29 and 30:
e EBV see Epstein-Barr virus EDR se
Page 31 and 32:
immature Mo-DCs 184 immune cells ±
Page 33 and 34:
MHC class I antigen-processing mach
Page 35 and 36:
±, onco- 209 ±, over-expressed ce
Page 37 and 38:
TICD see tumor-induced cell death T
Page 39 and 40:
Part 1 Tumor Antigenicity Cancer Im
Page 41 and 42:
4 1 Search for Universal Tumor-Asso
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
10 1 Search for Universal Tumor-Ass
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
18 2 Serological Determinants On Tu
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
30 Cancer Immune Therapie: Current
Page 69 and 70:
32 3 Processing and Presentation of
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
42 4 T Cells In Tumor Immunity cult
Page 81 and 82:
44 4 T Cells In Tumor Immunity cell
Page 83 and 84:
46 4 T Cells In Tumor Immunity to T
Page 85 and 86:
48 4 T Cells In Tumor Immunity Alth
Page 87 and 88:
50 4 T Cells In Tumor Immunity Tab.
Page 89 and 90:
52 4 T Cells In Tumor Immunity rest
Page 91 and 92:
54 4 T Cells In Tumor Immunity 53 T
Page 93 and 94:
Part 2 Immune Evasion and Suppressi
Page 95 and 96:
60 5 Major Histocompatibility Compl
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
68 Tab. 5.1 HLA class I loss attrib
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
96 6 Immune Cells in the Tumor Micr
Page 133 and 134:
98 6 Immune Cells in the Tumor Micr
Page 135 and 136:
100 6 Immune Cells in the Tumor Mic
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Tab. 7.1 Effects of tumor-derived m
Page 157 and 158:
122 7 Immunosuppresive Factors in C
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
156 8 Interleukin-10 in Cancer Immu
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Part 3 Strategies for Cancer Immuno
Page 213 and 214:
180 9 Dendritic Cells and Cancer: P
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
206 10 The Immune System in Cancer:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
232 11 Hybrid Cell Vaccination for
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280: 246 11 Hybrid Cell Vaccination for
Page 287 and 288: 254 12 Principles and Strategies Em
Page 301 and 302: 268 Cancer Immune Therapie: Current
Page 303 and 304: 270 13 Applications of CpG Motifs f
Page 321 and 322: 288 14 The T-Body Approach: Towards
Page 329: 296 14 The T-Body Approach: Towards
Page 333 and 334: 300 15 Bone Marrow Transplantation
Page 345 and 346: 312 16 Immunocytokines: Versatile M
Page 381 and 382:
348 17 Immunotoxins and Recombinant
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
382 Glossary tion to the variable d
Page 417 and 418:
384 Glossary suppressor gene produc
Page 419 and 420:
386 Glossary press the proper recep
Page 421 and 422:
388 Glossary gp96 See Chaperone. Gr
Page 423 and 424:
390 Glossary cytes and addressing l
Page 425 and 426:
392 Glossary T bodies are being tes
show all

Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

Create successful ePaper yourself

Delete template?

Save as template?